VIP: Dosing Protocols

Important Disclaimer#

Vasoactive Intestinal Peptide (VIP) is not approved by the FDA or any other regulatory agency for therapeutic use in any indication. The dosing information presented in this article is derived exclusively from published clinical trials, preclinical studies, and research protocols. This information is provided for educational and research reference purposes and does not constitute medical advice or a recommendation for self-administration. VIP administration requires clinical supervision, continuous hemodynamic monitoring, and expertise in managing vasoactive peptide infusions.

Pharmacokinetic Challenges in VIP Dosing#

The design of any VIP dosing protocol must account for the peptide's extremely short circulating half-life of approximately 1-2 minutes following intravenous administration. This rapid clearance, driven by degradation by neutral endopeptidase (NEP), dipeptidyl peptidase IV (DPP-IV), and various aminopeptidases, means that bolus intravenous injection produces only a transient spike in plasma VIP concentration followed by near-complete elimination within 5-10 minutes. Consequently, sustained pharmacological effects require either continuous intravenous infusion or alternative delivery strategies such as inhalation that achieve local tissue concentrations independent of systemic pharmacokinetics.

The rapid degradation also creates a narrow therapeutic window. Because VIP's most significant dose-limiting toxicity is systemic hypotension (a direct consequence of its vasodilatory mechanism of action), and because even small increases in infusion rate can produce disproportionate hemodynamic effects given the steep dose-response relationship, precise dose titration with real-time monitoring is essential for any intravenous VIP protocol.

Intravenous Infusion Protocols#

Aviptadil IV for Acute Respiratory Failure (ZYESAMI Trial)#

The most well-documented intravenous VIP dosing protocol comes from the Phase 2/3 ZYESAMI trial, which evaluated intravenous aviptadil (the United States Adopted Name for synthetic human VIP) in patients with COVID-19-associated respiratory failure. The trial design employed a dose-escalating continuous infusion protocol administered over three consecutive days.

The dosing regimen used in this trial followed a stepped escalation approach:

• Day 1: Initiation at 50 pmol/kg/min with gradual escalation to the target infusion rate over 12 hours, with continuous blood pressure and heart rate monitoring.
• Day 2: Continuation at the established tolerated rate, with adjustment based on hemodynamic response observed on Day 1. Target infusion rates reached up to 100 pmol/kg/min in patients who tolerated the initial dose.
• Day 3: Final day of infusion at the maximum tolerated rate, up to 150 pmol/kg/min in selected patients.

Each infusion session was conducted over approximately 12 hours with the patient in a monitored clinical setting. Blood pressure was assessed at frequent intervals (typically every 15 minutes during dose escalation and at least hourly during stable infusion). The infusion was paused or the rate reduced if systolic blood pressure fell below predefined thresholds or if the patient developed symptomatic hypotension.

The trial used aviptadil formulated in sterile saline for intravenous infusion. The product was supplied as a lyophilized powder requiring reconstitution prior to dilution and infusion.

Earlier IV Research Protocols#

Prior to the ZYESAMI trial, smaller investigational studies used VIP infusion rates in the range of 1-10 pmol/kg/min for cardiovascular pharmacology studies in healthy volunteers and patients with various conditions. These early studies established that:

• Infusion rates of 1-3 pmol/kg/min produce measurable increases in plasma VIP concentration and detectable vasodilatory effects without significant hypotension in most healthy subjects.
• Infusion rates of 6-10 pmol/kg/min produce clinically significant vasodilation with flushing, modest blood pressure reduction, and increased heart rate.
• Infusion rates exceeding 10 pmol/kg/min reliably produce hypotension and reflex tachycardia, with the severity being dose-dependent.

These earlier dose-ranging observations informed the escalation strategy employed in the ZYESAMI trial and other later studies.

Inhaled VIP Protocols#

Inhaled VIP for Pulmonary Arterial Hypertension#

The rationale for inhaled VIP administration in pulmonary arterial hypertension (PAH) is to deliver the peptide directly to the pulmonary vasculature, achieving high local concentrations in the target tissue while minimizing systemic exposure and the associated risk of systemic hypotension. This approach exploits the large surface area of the pulmonary epithelium and the direct access of inhaled molecules to the pulmonary vascular smooth muscle.

In the initial open-label study by Petkov and colleagues published in 2003, twenty patients with idiopathic PAH received inhaled VIP at doses of 100-200 micrograms daily for three months. The VIP was administered via nebulization, producing an aerosolized solution that was inhaled over approximately 10-15 minutes per treatment session. Key findings from this study included:

• Reduction in mean pulmonary arterial pressure by approximately 13 mmHg
• Improvement in pulmonary vascular resistance
• Increased cardiac output
• Improvement in 6-minute walk distance
• Enhancement of right ventricular function on echocardiography

These encouraging results led to a subsequent randomized, double-blind, placebo-controlled Phase 2 trial of inhaled aviptadil in PAH. However, this controlled trial failed to demonstrate statistically significant improvements in the primary hemodynamic endpoints, raising questions about the reproducibility of the open-label findings and the adequacy of drug delivery to the target tissue via nebulization.

Delivery Considerations for Inhaled VIP#

Effective pulmonary delivery of VIP requires optimization of several parameters:

• Particle size: Aerosolized droplets in the 1-5 micrometer range are optimal for reaching the distal airways and alveolar regions where the pulmonary vasculature is most accessible. Larger particles deposit in the oropharynx and conducting airways, reducing pulmonary bioavailability.
• Nebulizer type: Jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers each produce different particle size distributions and output rates. The choice of nebulizer can significantly affect the delivered dose and the deposition pattern within the respiratory tract.
• Peptide stability during aerosolization: The mechanical forces and temperature changes involved in nebulization can degrade peptides. VIP stability during the aerosolization process must be verified for each delivery device and formulation.
• Local enzymatic degradation: The pulmonary epithelium expresses NEP and other peptidases that can degrade VIP before it reaches the vascular smooth muscle target. The local half-life of VIP in the pulmonary microenvironment may be longer than the systemic half-life but is still limited.

Alternative Delivery Approaches Under Investigation#

The pharmacokinetic limitations of native VIP have driven extensive research into alternative delivery and formulation strategies. While none of these have progressed to established clinical protocols, they represent important directions for future dosing paradigm development.

Long-Acting VIP Analogs#

Several structural modifications have been explored to extend VIP's half-life while preserving receptor binding and biological activity:

• D-amino acid substitution: Replacement of L-amino acids at key degradation sites with their D-enantiomers can confer resistance to enzymatic cleavage. Stearyl-norleucine-VIP (SNV), in which the N-terminal histidine is replaced with norleucine and a stearyl chain is added, demonstrated neuroprotective efficacy in animal models with improved pharmacokinetic properties.
• PEGylation: Conjugation of polyethylene glycol chains to VIP increases hydrodynamic radius, reduces renal clearance, and shields enzymatic cleavage sites. PEGylated VIP analogs have shown extended half-lives in preclinical studies while retaining VPAC receptor activity.
• Lipidation: Fatty acid conjugation (analogous to the approach used successfully with GLP-1 in semaglutide and liraglutide) enables albumin binding and extends circulating time. This approach has been explored for VIP with promising preclinical results.

Nanoparticle and Liposomal Formulations#

Encapsulation of VIP in biodegradable nanoparticles, liposomes, or polymeric microspheres provides physical protection from enzymatic degradation while enabling sustained release over hours to days. VIP-loaded PLGA nanoparticles have been investigated for targeted delivery in inflammatory bowel disease, with oral or rectal administration designed to release VIP at the site of intestinal inflammation. Liposomal VIP formulations have shown enhanced anti-inflammatory efficacy in preclinical colitis models compared to free VIP.

Monitoring Requirements#

Any clinical or research protocol involving VIP administration should include the following monitoring:

Dosing Summary Table#

Current Limitations#

The absence of an approved VIP formulation means that all dosing protocols remain investigational. Key unresolved questions include the optimal infusion rate for specific indications, whether intermittent bolus dosing could be effective for conditions not requiring sustained VIP exposure, the minimum effective inhaled dose for pulmonary hypertension, and whether next-generation long-acting analogs can achieve therapeutic concentrations without dose-limiting vasodilation. Until these questions are addressed through rigorous clinical trials, VIP dosing remains an area of active research rather than established clinical practice.

Related Reading#

• VIP overview and research guide
• VIP side effects profile
• VIP research evidence